The current study intended to explore how ERBB3 mediates the PI3K/AKT/mTOR pathway and changes the tumor immune microenvironment to affect the EMT status of cervical cancer, which may provide further understanding of MMPs involved in immunotherapy. This evidence concerns the gene PIK3CB and cervical carcinoma.